Changes in active cysteine cathepsins in lysosomes from tissues thyroid papillary carcinomas with various biological characteristics
Kalinichenko OV, Myshunina TM, Tron'ko MD
V.P. Komisarenko Institute of Endocrinology andMetabolism of AMS of Ukraine, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz59.05.011
Abstract
To clarify possible role of cysteine cathepsin H, B and L in the proteolytic processes that contribute to the progression of tumor growth in the thyroid, we studied their activity in lysosomes isolated from the tissue of papillary carcinomas. It was shown that for these enzymes there is a dependence of the changes in their activity on a number of biological characteristics of the tumors. Thus, the sharp increase in the activity ofcathepsin H observed in lysosomes of tissue carcinomas category T2 and T3, with intra-and ekstrathyroid and lymphatic invasion of tumor cells. An increase in the activity of cathepsin B is set in the lysosomes of tissue heterogeneous follicular structure, especially in the presence of solid areas, in comparison with typical papillary tumors and in the lysosomes of tissue carcinomas in intrathyroid and cathepsin L-at extrathyroid invasion. A common feature of the enzymes is to increase the activity of cathepsins in lysosomes of tissue nonencapsulated papillary carcinomas. These enzymes probably do not take part in the invasion of tumor cells into blood vessels and in the mechanisms of tumor metastasis to regional lymph nodes. The latter shows no changes in the activity of cathepsins in lysosomes of tissue carcinomas category N1. The results indicate the different role of cathepsin H, B and L in thyroid carcinogenesis, where each enzyme has its specific function.
Keywords:
cysteine cathepsins B, H, L, thyroid papillarycarcinoma, invasion.
References
Zhanaeva S.Ya., D'yakov A.I., Alekseenko T.A., Korolen-ko T.A. Prognosticheskaya znachimost' tsisteinovihproteaz lizosom v opredelenii effektivnosti protivoopuholevoi terapii . Biomed. himiya. 2009.55, vip. 1. P. 89-97.
Zhloba A.A., Dunaevskii V.A. Aktivnost' sekretiruemih form tsisteinovih katepsinov v krovi v kachestve markera protsessov tkanevogo rosta . Voprosi onkologii. 1996. N 1. P. 70-76.
Kalinichenko O.V., Mishunina T.M., Tron'ko M.D. Katepsinopodibna aktivnist' u plazmi krovi hvorih z papilyarnoyu kartsinomoyu shchitopodibnoi zalozi . Fiziol. zhurn. 2010. 56, N 6. P. 76-81.
Kirpichenyuk L.N., Gidranovich L.G., Shilenok V.N. Aktivnost' proteoliticheskih protsessov pri zabolevaniyah shchitovidnoi zhelezi . Voprosi med. himii.2000. N 5. P. 45.
Lyanna O.L., Chorna V.I., Hvorostenko M.I. Osobli-vosti regulyatsii aktivnosti tsisteinovih proteaz ta viznachennya ih klinichnogo znachennya za kantserogenezu shchitopodibnoi zalozi . Ukr. radiol. zhurn. 2009. N 3. P. 308-311.
Mishunina T.M. Chi diisno zrostannya kontsentratsii TTG u krovi hvorih z kartsinomoyu shchitopodibnoi zalozi mozhe buti naslidkom pidvishchenoi aktivnosti katepsinu L ? . Endokrinologiya. 2013. N 1. P. 18-22.
Barret A., Kirschke H. Cathepsins B, H, and L. In: Methods in enzymology. Ed.: L. Loran. New-York, London: Acad. rress. 1981. 80, part C. R 535-561.
Bialek J., Hombach-Klonisch S., Fiebig B., Weber E., Hoang-Vu C., Klonisch T. Lysosomal acid hydrolases of the cathepsin family are novel targets of INSL3 in human thyroid carcinoma cells . Ann. NY Acad .Sci. 2009. N 1160. P. 361-366.
Boltze C., Riecke A., Ruf C., Port M., Nizze H., Kugler C., Miethke C., Wiest N., Abend M. Sporadic and radiationassociated papillary thyroid cancers can be distinguished using routine immunohistochemistry . Oncol. Rep. 2009. 22, N 3. P. 459-467.
Brown L., Helmke S., Hunsucker S., Netea-Maier R., Chiang S., Heinz D., Shroyer K., Duncan M., Haugen B. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue . Mol. Carcinog. 2006. 45, N 8. P. 613-626.
Budihna M. Prognostic value of catepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma . Biol. Chem. 1996. 377. P. 385-390.
Buth H., Wolters B., Hartwig B., Meier-Bornheim R., Veith H., Hansen M., Sommerhoff C., Schaschke N., Machleidt W., Fusenig N., Boukamp P., Brix K. HaCaT keratinocytes secrete lysosomal cysteine proteinases during migration . Eur. J. Cell Biol. 2004. 83. P. 781-795.
Glogowska A., Pyka J., Kehlen A., Los M., Perumal .P, Weber E., Cheng S., Hoang-Vu C, Klonisch T. The cytoplasmic domain of proEGF negatively regulates motility and elastinolytic activity in thyroid carcinoma cells . Neoplasia. 2008. 10, N 10. P. 1120-1130.
Gocheva V., Joyce J. Cysteine cathepsins and the cutting edge of cancer invasion . Cell Cycle. 2007. 6, N 1. P. 60-64.
Gocheva V., Zeng W., Ke D., Klimstra D., Reinheckel T., Peters C., Hanahan D., Joyce J. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis . Genes Dev. 2006. 20, N 5. P. 543-556.
Goulet B., Sansregret L., Leduy L., Bogyo M., Weber E., Chauhan S., Nepveu A. Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation . Mol. Cancer Res. 2007. 5, N 9. P. 899-907.
Hartree T. Determination of protein: A modification of Lowry method that gives a linear photometric response . Anal. Biochem. 1972. 48, N 2. P. 422-427.
Jordans S., Jenko-Kokalj S., Kuhl N., Tedelind S., SendtW., Bromme D., Turk D., Brix K. Monitoring compartmentspecific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions . BMC Biochem. 2009. 22, N 10. P. 23.
Koblinski J., Ahram M., Sloane B. Unraveling the role of proteases in cancer . Clin. Chim. Acta. 2000. 291, N 2. P. 113-135.
Korolenko T. Cysteic proteinases lisosom and inhibitors: the role in tumor inflammation and development . Biochemistry fundamental and applied aspects: scient. conf. works. October, 15-17, 1998. SPb., 1998. 1.P. 180-187.
Kusunoki T., Nishida S., Nakano T., Funasaka K., Kimoto S., Murata K., Tomura T. Study on cathepsin B activity in human thyroid tumors . Auris Nasus Larynx. 1995 22, N 1. P. 43-48.
Lankelma J., Voorend D., Barwari T., Koetsveld J., Van der Spek A., De Porto A., Van Rooijen G., Van Noorden C. Cathepsin L, target in cancer treatment? . Life Sci. 2010. 86, N 7-8. P. 225-233.
Mohamed M., Sloane V. Cysteine cathepsins: multifunctional enzymes in cancer . Nat. Rev. Cancer. 2006. 6. P. 764-775.
Moin K. Tumor cell membrane cathepin B . Biol. Chem. 1998. 379, N 8-9. P. 1093-1099.
Nomura T., Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells . J. Med. Invest. 2005. 52, N 1-2. P. 1-9.
Nyberg, P. Trypsins and their role in carcinoma growth . Exp. Cell Res. 2006. 312, N 8. P. 1219-1228.
Plehn A., Gunther D., Aurich H., Hoang-Vu C., Weber E.nfluence of proliferation, differentiation and dedifferentiation factors on the expression of the lysosomal cysteine proteinase cathepsin L (CL) in thyroid cancer cell lines . Adv. Exp. Med. Biol. 2000. 477. P. 487-495.
Podgorski I., Linebaugh B., Sameni M., Jedeszko C., Bhagat S., Cher M., Sloane B. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer . Neoplasia. 2005. 7. P. 207-223.
Shuja S., Ca J., Iacobuzio-Donahue C., Zacks J., Beazley R., Kasznica J., O’Hara C., Heimann R., Murnane M. Cathepsin B activity and protein levels in thyroid carcinoma, Graves’ disease, and multinodular goiters . Thyroid. 1999. 9, N 6. P. 569-577.
Shuja S., Murnane M. Marked increases in cathepsin B an L activities distinguish papillary carcinoma of the thyroid from normal thyroid or thyroid with non-neoplastic disease . Int. J. Cancer. 1996. 66, N 4. P. 420-426.
Sloane B. Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene . J. Cell Sci. 1994. 107, Pt2. P. 373-384.
Srisomsap C., Subhasitanont P., Otto A., Mueller E., Punyarit P., Wittmann-Liebold B., Svasti J. Detection Zmini aktivnosti tsisteinovih katepsiniv ISSN 0201-8489 Fiziol. zhurn., 2013, T. 59, N 5 19 of cathepsin B up-regulation in neoplastic thyroid tissues by proteomic analysis . Proteomics. 2002. 2, N 6. P. 706-712.
Starling J., Clifton K., Norback D. Enzymatic and ultrastructural study of lysosomes in rats bearing radiationinduced thyroid follicular carcinoma . J. Surg. Oncol.1981. 16, N 1. P. 15-25.
Tedelind S., Jordans S., Resemann H., Blum G., Bogyo M., Fuhrer D., Brix K. Cathepsin B trafficking in thyroid carcinoma cells . Thyroid Res. 2011. 4, Suppl. 1. P. S2.
Tedelind S., Poliakova K., Valeta A., Hunegnaw R., Yemanaberhan E., Heldin N., Kurebayashi J., Weber E.,Kopitar-Jerala N., Turk B., Bogyo M., Brix K. Nuclearcysteine cathepsin variants in thyroid carcinoma cells .Biol. Chem. 2010. 391, N 8. P. 923-935.
Vasiljeva O., Papazoglou A., Kruger A., Brodoefel H., Korovin M., Deussing J., Augustin N., Nielsen B., Almholt K., Bogyo M., Peters C., Reinheckel T. Tumor cellderived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer . Cancer Res. 2006. 66. P. 5242-5250.
Wu S., Huang Y., Yeh C., Tsai M., Liao C., Cheng W., Chen W., Lin K. Cathepsin H regulated by the thyroid hormone receptors associate with tumor invasion in human hepatoma cells . Oncogene. 2011. 30, N 17. P. 2057-2069.
|
